CV

Esperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023

Retrieved on: 
Saturday, August 26, 2023
CV, Shoulder, Diabetes, Life, Splenic infarction, Spasm, Fetus, Lactation, Pregnancy, European Society of Cardiology, Bempedoic acid, Doctor of Philosophy, Pain, Congress, Prediabetes, Patient, Risk, Disease, Gout, Diet, MBBS, Ezetimibe, Drug, Simvastatin, Cardiovascular disease, Pravastatin, Back pain, Fellow of the Academy of Medical Sciences, ESPR, Tablet, ESC, Safety, Rotator cuff, Atrial fibrillation, CVD, Abdominal pain, Uric acid, Anemia, Mortality, Imperial College London, Achilles tendon, Glycated hemoglobin, Bronchitis, Tendon rupture, Monash University, ATP, Rupture, Kidney, NEJM, CLEAR, Moyamoya disease, Upper respiratory tract infection, Health, Dietary supplement, Pharmaceutical industry, MD, Esperies, Hyperuricemia

ANN ARBOR, Mich., Aug. 26, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of results from two oral presentations at the Late-Breaking Science Session entitled, “Clinical trial updates on prevention and lipid lowering” at the European Society of Cardiology (ESC) 2023 Congress, taking place August 25-28, 2023, in Amsterdam, Netherlands.

Key Points: 
  • “We are pleased to share additional results from our landmark CLEAR Outcomes study in late-breaker presentations at ESC 2023,” said Sheldon Koenig, President and CEO of Esperion.
  • Of the 13,970 patients included in CLEAR Outcomes, 45.6% had diabetes, 41.5% were pre-diabetic, and 12.9% had normoglycemia.
  • At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

New secondary analysis of CLEAR Outcomes data for bempedoic acid show significant risk reduction of total cardiovascular events and no increase of new-onset diabetes in patients at high-risk of cardiovascular disease

Retrieved on: 
Saturday, August 26, 2023
Diabetes, Health, Pharmaceutical, Clinical Trials, Cardiology, Medical Affairs Bureau, CV, Myocardial infarction, NOD, Bempedoic acid, ATP, Cardiovascular disease, European Society of Cardiology, RRR, CVD, Agent handling, Congress, Incidence, Public health, Blood, Data analysis, Patient, Risk, Daiichi Sankyo, ESC, ACL, Death, Imperial College London, Glycated hemoglobin, Pharmaceutical industry, Dietary supplement

The results, presented at the European Society of Cardiology (ESC) Congress 2023, further support the long-term use of bempedoic acid in patients at high-risk of cardiovascular (CV) events and demonstrate particular benefit in those with diabetes.

Key Points: 
  • The results, presented at the European Society of Cardiology (ESC) Congress 2023, further support the long-term use of bempedoic acid in patients at high-risk of cardiovascular (CV) events and demonstrate particular benefit in those with diabetes.
  • “Furthermore, the data show that treatment with bempedoic acid does not impact HbA1c levels or the incidence of new-onset diabetes.
  • This is particularly important given diabetes patients’ increased risk of a CV event regardless of the presence or not of CVD.
  • These findings reinforce bempedoic acid as an effective treatment option for LDL-C lowering and CV risk reduction in Europe.

Recent Study from England’s National Health Service Highlights Positive Impact of Implementing HeartFlow’s FFRCT Analysis for Diagnosis of Coronary Artery Disease

Retrieved on: 
Saturday, August 26, 2023
Science, Cardiology, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Liverpool Heart and Chest Hospital, Percutaneous coronary intervention, Rare Diseases Clinical Research Network, National Health Service, FISH, NHS England, Non-fatal offences against the person in English law, CV, MI, Fractional flow reserve, Principal investigator, Cardiovascular disease, CAD, CRN, CCTA, MRC, European Society of Cardiology, PCI, Congress, Patient, Physician, Risk, CHIPS, Diagnosis, Mortality, ICA, NHS, Coronary artery disease, ESC, Medical device, Medical imaging, Pharmaceutical industry

The FISH&CHIPS study was designed to assess at a national level the incremental impact of adding HeartFlow FFRCT to a CCTA-first (Coronary Computed Tomography Angiography) diagnostic pathway to evaluate and manage CAD.

Key Points: 
  • The FISH&CHIPS study was designed to assess at a national level the incremental impact of adding HeartFlow FFRCT to a CCTA-first (Coronary Computed Tomography Angiography) diagnostic pathway to evaluate and manage CAD.
  • FISH&CHIPS two-year key outcomes associated with availability of FFRCT include:
    A significant 14% relative reduction in cardiovascular mortality and a significant 8% relative reduction in all-cause mortality.
  • An increase in cath lab efficiency, driven by a 5% relative reduction in invasive cardiac angiography (ICA) and an 8% relative increase in Percutaneous Coronary Intervention (PCI).
  • High prognostic value for FFRCT whereby patients with severely abnormal FFRCT values (≤0.50) had a 2x risk of all-cause death and a 3x risk of non-fatal MI compared to patients with normal FFRCT values.

Philips integrates AI in cardiac ultrasound and across cardiac care at ESC 2023

Retrieved on: 
Thursday, August 24, 2023
Heart, CT, CV, 3D, MedStar Washington Hospital Center, European Society of Cardiology, Congress, Patient, MD, Mitral valve, Algorithm, AEX, Diagnosis, PHG, Cardiology, Ecosystem, ESC, NYSE, Medical device, Medical imaging

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today highlighted how it integrates AI in cardiac ultrasound and across cardiac care to help improve clinical confidence and increase efficiency.

Key Points: 
  • Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today highlighted how it integrates AI in cardiac ultrasound and across cardiac care to help improve clinical confidence and increase efficiency.
  • Using AI to help streamline workflows and enhance diagnostic confidence is core to Philips cardiac ultrasound technology.
  • At ESC, Philips will also highlight its Advanced Visualization Workspace , which integrates AI-enabled algorithms and workflows into a single workspace.
  • The integration of Cardiac MR and CT on Philips Advanced Visualization Workspace has lowered overall analysis time by 20-30% [1].

RTLS in healthcare market to grow by USD 3.2737 billion between 2022 to 2027; Growth opportunities led by Advantech Co. Ltd. and AiRISTA Flow Inc.- Technavio

Retrieved on: 
Friday, August 18, 2023
CV, Health, Stanley Black, Claro, América Móvil, Halma plc, Research, SGS, Baxter International, RTLS, ASSA, EHR, Risk, Siemens, Real-time locating system, Growth, SA, Health information management, Semiconductor, Retail, COVID-19

Market vendors also have to leverage the existing growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Key Points: 
  • Market vendors also have to leverage the existing growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
  • AiRISTA Flow Inc. - The company offers RTLS in healthcare called the AiRISTA RTLS solution.
  • RTLS in Healthcare Market 2023-2027: Market Dynamics
    The integration with electronic health records (EHR) is an emerging RTLS in the healthcare market trend.
  • RTLS in Healthcare Market 2023-2027: Segmentation
    RTLS in Healthcare Market is segmented as below:

HONEYWELL RESEARCH INDICATES ARTIFICIAL INTELLIGENCE WILL SHAPE GLOBAL RETAIL OVER THE NEXT 12 MONTHS

Retrieved on: 
Tuesday, August 15, 2023
Workforce, CV, Member, ESOMAR, Market Research Society, ML, OnePoll, Research, Job satisfaction, Customer experience, Machine learning, Data, Norris Production Solutions, Honeywell, Artificial intelligence, Fraud, British Polling Council, Retail, Medical device, Online shopping, Customer service, AI

The research also indicates that retailers see this new technology as complementing and enhancing their workforce and not eliminating jobs.

Key Points: 
  • The research also indicates that retailers see this new technology as complementing and enhancing their workforce and not eliminating jobs.
  • Honeywell's AI in Retail survey involved some 1,000 retail directors across the United States, Europe, the Middle East and Africa in leadership roles – including IT, operations, and customer experience.
  • "As AI continues to evolve, expect an exciting future where innovative technologies unlock new levels of efficiency, engagement and satisfaction in retail."
  • Honeywell's AI in Retail online survey of 1,000 Directors in Retail, IT, Operations and Customer Experience was commissioned by Honeywell and conducted by market research company OnePoll, in accordance with the Market Research Society's code of conduct.

Toyota Announces Changes to Organizational Structure and Senior Professionals/Senior Management

Retrieved on: 
Wednesday, May 31, 2023
Toyota, Organization, CV, TMC, Automotive industry, Oil, Hydrogen

Toyota City, Japan, May 31, 2023 - (JCN Newswire) - On July 1, Toyota Motor Corporation (TMC) intends to make the following organizational and senior professional/senior management changes.

Key Points: 
  • Toyota City, Japan, May 31, 2023 - (JCN Newswire) - On July 1, Toyota Motor Corporation (TMC) intends to make the following organizational and senior professional/senior management changes.
  • - Hydrogen Factory will be newly established as a dedicated organization to accelerate customer-oriented product development and production in fuel cell or hydrogen-related products.
  • - The processes will all be conducted in one place under a single leader, enabling speedy decision-making and execution.
  • - By strengthening alliances with local partners in Europe and China, where the hydrogen mobility market is rapidly expanding, and promote sustainable commercialization.

EQS-News: Leifheit Aktiengesellschaft: Growth in turnover and earnings in the first half of 2023

Retrieved on: 
Thursday, August 10, 2023
Advertising, CV, Private label, Household, Pegasus, Tax, Beiersdorf, Supervisory board, EBIT, Board of Management St. Molaga's National School v The Secretary General of the Department of Education and Science, EUR, ISIN, Management, Growth, Leifheit, Security (finance), Cryptocurrency, Retail, Renewable energy, Central Europe

The Leifheit Group generated earnings before interest and taxes (EBIT) of EUR 4.8 million (previous year: EUR 2.1 million) in the first half of 2023.

Key Points: 
  • The Leifheit Group generated earnings before interest and taxes (EBIT) of EUR 4.8 million (previous year: EUR 2.1 million) in the first half of 2023.
  • Less taxes, this equalled a net result for the period of EUR 2.6 million in the first half of 2023.
  • In the Household segment, the Leifheit Group generated turnover of EUR 115.0 million in the first half of 2023 (previous year: EUR 113.4 million), which equates to growth of 1.4%.
  • Turnover rose from EUR 8.3 million in the same period of 2022 to EUR 8.7 million in the first half of 2023.

Aware Transforms Experience Management with the Industry's Most Accurate Spanish Language NLP Models

Retrieved on: 
Thursday, August 3, 2023
Cisco Webex, Workforce, Microsoft Teams, LLM, Natural language processing, Communication, Anecdote, CV, Experience management, Data science, Sentiment, WorkJam, Intelligence, Emerging, Human, Language, NLP, Organization, Internet, Cisco, Risk, Qualtrics, Zoom, AI, Health, Management, Slack, COLUMBUS

COLUMBUS, Ohio, Aug. 3, 2023 /PRNewswire/ -- Aware, the AI Data Platform delivering contextual intelligence to power Experience Management, today announced the release of new Spanish sentiment and toxic speech models to its ever-expanding ecosystem of natural language processing (NLP) and computer vision (CV) models. With Aware's cutting-edge capabilities to create and deploy accurate models quickly and cost-effectively, multilingual organizations now gain continuous listening capabilities needed to deliver a better employee experience.

Key Points: 
  • COLUMBUS, Ohio, Aug. 3, 2023 /PRNewswire/ -- Aware, the AI Data Platform delivering contextual intelligence to power Experience Management, today announced the release of new Spanish sentiment and toxic speech models to its ever-expanding ecosystem of natural language processing (NLP) and computer vision (CV) models.
  • With Aware's cutting-edge capabilities to create and deploy accurate models quickly and cost-effectively, multilingual organizations now gain continuous listening capabilities needed to deliver a better employee experience.
  • Aware CEO, Jeff Schumann, underscores the importance of understanding the authentic voice of employees for Experience Management.
  • To see Aware's models in action, or to explore how you can use these insights to transform your employee experience, visit AwareHQ.com

Abu Dhabi’s artificial intelligence university establishes dedicated robotics and computer science departments to meet surging global demand

Retrieved on: 
Thursday, August 3, 2023
Natural language processing, University, CV, Education, Doctor of Philosophy, University of Colorado Boulder Computer Science Department, Agriculture, ABU, Research, USD, NLP, Government, US, MBZUAI, Student, Robotics, Machine learning, Algorithm, Artificial intelligence, Faculty, Ecosystem, AI, Transport, Professor, Medical device

The new departments complement the university’s existing computer vision (CV), machine learning (ML), and natural language processing (NLP) departments, which are ranked among the top 20 globally by CSRankings.

Key Points: 
  • The new departments complement the university’s existing computer vision (CV), machine learning (ML), and natural language processing (NLP) departments, which are ranked among the top 20 globally by CSRankings.
  • Aligned with the formation of the new departments, the university has launched master’s and Ph.D. programs in robotics and computer science.
  • MBZUAI President and University Professor, Eric Xing, said: "The addition of these two new departments represents MBZUAI’s lasting effort in developing a solid foundation for research excellence and innovation in artificial intelligence.
  • Research indicates strong demand for robotics expertise in the coming years, with the robotics technology market expected to surpass US$225.6 billion in value by 2030iii.